Clinical Trials Logo

Meningoccocal Disease clinical trials

View clinical trials related to Meningoccocal Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01894919 Completed - Clinical trials for Meningococcal Meningitis

Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

Start date: June 2013
Phase: Phase 3
Study type: Interventional

The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in groups I to III of the parent V72_28 study. This study will also explore the antibody persistence 24 to 36 months after two catch-up doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10 years old) in group IV of the parent V72_28 study.